Environmental

BAX’s R&D intensity near 4.5% of revenue supports product stewardship and lower-impact innovation, comparing favorably with many medtech peers that underinvest in sustainable design.

The company’s capital discipline appears moderate, but the absence of disclosed high-emission industrial exposure keeps its environmental risk profile below heavier manufacturing peers.

BAX’s environmental footprint is likely more manageable than diversified healthcare equipment peers with larger energy-intensive production bases, though disclosure depth limits a higher relative score.

No major environmental controversies were provided, which supports a stronger peer-relative position versus companies facing active remediation, waste, or compliance burdens.

Social

BAX’s healthcare focus makes product quality and patient safety the dominant social issue, and its established medtech profile generally compares better than peers with weaker quality systems.

R&D spending near 4.5% of revenue indicates continued investment in clinically relevant innovation, which supports social value creation relative to slower-moving device peers.

Low stock-based compensation at roughly 1.0% of revenue suggests less dilution-driven stakeholder friction than peers with more aggressive pay structures.

No material labor, supply-chain, or product-safety controversies were provided, supporting a stronger social standing than peers with recurring operational incidents.

Governance

BAX’s leverage is elevated, with net debt to EBITDA above 10x, which can constrain governance flexibility and heighten creditor scrutiny versus better-capitalized peers.

Debt to equity above 1.5x suggests a more leveraged capital structure than many healthcare peers, increasing board pressure around capital allocation and risk oversight.

Stock-based compensation near 1.0% of revenue is relatively restrained, which supports alignment versus peers with heavier equity dilution.

The provided metrics do not indicate severe governance failure, but limited disclosure on board independence, controversies, and shareholder rights prevents a stronger relative score.

Overall Score

BAX ranks stronger on social and environmental factors than on governance, but elevated leverage keeps its overall ESG positioning below top-tier healthcare peers.

Score Driver: Elevated Leverage And Balance-Sheet Risk